Claros | $30,000,000 | (Mar 20, 2026)
Avtal | $24,000,000 | (Mar 20, 2026)
Evozyne
United States
- Chicago, IL
- 28/09/2023
- Series B
- $81,000,000
Evozyne combines evolution and deep learning technology to create highly functional novel proteins — Natural Machines™ — to solve longstanding challenges in therapeutics and sustainability. By amplifying a protein’s function based on the rules of nature, we address complex, high-impact problems. From developing life-changing patient treatments to making carbon capture a reality, Evozyne is committed to making a healthier, more sustainable world.
- Industry Biotechnology
- Website https://www.evozyne.com/
- LinkedIn https://www.linkedin.com/company/evozyne/about/
Related People
Mike GamsonFounder
United States -
Greater Chicago Area
I'm passionate about leading teams to pursue inspiring goals. I love working with intellectually curious people who can do anything, but show up everyday with humility and a drive to be better than they were yesterday. I believe that driving results matters as does taking the time in life to stop to smell the roses. I aspire to be a great colleague and I hope to be a student of new things forever.
PADO AI | $6,000,000 | (Mar 20, 2026)
Raven.io | $20,000,000 | (Mar 19, 2026)
Manifold Security | $8,000,000 | (Mar 19, 2026)
SetSale | $2,000,000 | (Mar 19, 2026)
xmemory | $4,000,000 | (Mar 19, 2026)
Laminar (YC S24) | $3,000,000 | (Mar 19, 2026)
Obin AI | $7,000,000 | (Mar 19, 2026)
Multiply(US) | $9,500,000 | (Mar 19, 2026)
Respan (formerly Keywords AI) | $5,000,000 | (Mar 19, 2026)